CLINICAL EVALUATION OF AC-1370 IN RTI
1984 Volume 32 Issue Supplement9 Pages 277-280
Details
1984 Volume 32 Issue Supplement9 Pages 277-280
AC-1370 was used in 10 patients, evaluable cases being 9 cases of broncho-pulmonary infections. Daily doses of AC-1370 ranged from 1g to 2g.
Clinical effects in 4 cases of acute pneumonia were assessed as good in all 4 cases. In 1 case of diffuse panbronchiolitis, 1 case of chronic bronchitis and 1 case of chronic pneumonia response were good respectively. In 1 case of lung abscess and 1 case of secondary infection (pneumonia) of lung cancer response were poor. Causative organisms were K. pneumoniae (1 case), H. influenzae (2 cases) and Enterobacter (1 case). After AC-1370 K. pneumoniae and H. influenzae were eradicated. Enterobacter was replaced to M. morganii and Acinetobacter. No evidence of side effect was noted. Labolatorical abnormalities were detected in 2 cases transient γ-GTP and Al-P elevation was noted. 1 case of granulocytopenia (26% of 4, 200 WBC) was noted after 2 weeks drug administration.
